v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Operating Activities:    
Net loss $ (9,369) $ (15,567)
Adjustments to reconcile net loss to cash flows used in operating activities:    
Depreciation and amortization 75 123
Stock-based compensation expense 47 84
Change in fair value of warrant liabilities (4,437) (940)
Financing expense 6,077 10,553
Non-cash IP R&D from Rendiatech acquisition 757 0
Changes in operating assets and liabilities:    
Accounts receivable (52) 534
Inventory, net 218 (310)
Other current assets 8 (430)
Other assets (213) 106
Other liabilities (144) (74)
Accounts payable and accrued expenses 746 1,288
Net cash used in operating activities (6,287) (4,633)
Investing Activities:    
Purchases of property and equipment (39) (4)
Purchase of intangible assets (90) 0
Cash paid for acquisition of Rendiatech, net of cash acquired (164) 0
Net cash used in investing activities (293) (4)
Financing Activities:    
Proceeds from issuance of common stock and warrants, net 9,363 3,999
Issuance of common stock from ATM, net 55 0
Net cash provided by financing activities 9,418 3,999
Effect of exchange rate changes on cash 0 (7)
Net increase (decrease) in cash and cash equivalents 2,838 (645)
Cash and cash equivalents, and restricted cash - beginning of period 1,190 5,095
Cash and cash equivalents, and restricted cash - end of period 4,028 4,450
Supplemental cash flow information    
Common stock issued as consideration in asset acquisition 162 0
Issuance of common stock for conversion of Series F-1 Preferred Stock 0 1,100
Deferred costs issued as consideration in asset acquisition 313 0
Deemed dividend on Series J Preferred Stock $ 3 $ 2